INVA - CIK 0001080014
Innoviva, Inc. trades as INVA and has a market capitalization of $1.69 B, making it the #2233 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $411.33M, up 14.7% from the prior year. This page tracks Innoviva, Inc. through 1,653 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Innoviva, Inc.'s revenue grew from $133.57M to $411.33M, a compound annual growth rate of 13.3%.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-20 |
| New insider ownership | 3 | 2026-05-20 |
| Major company event | 8-K | 2026-05-18 |
| SCHEDULE 13D/A | - | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-06 |
Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year
Generated $63.4 million in revenue from durable royalties portfolio
Strong royalties portfolio performance with $67.3 million in revenue
The largest companies sharing Innoviva, Inc.'s SEC industry classification (pharmaceutical preparations).
Innoviva, Inc. (INVA) has a market capitalization of $1.69 B as of 2026-06-10, ranking #2233 among US-listed companies.
Innoviva, Inc. reported revenue of $411.33M for fiscal year 2025, an increase of 14.7% year over year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.